Lyra Therapeutics Files Definitive Proxy Statement
Ticker: LYRA · Form: DEF 14A · Filed: Apr 4, 2025 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | DEF 14A |
| Filed Date | Apr 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
Lyra Therapeutics DEF 14A filed - vote on directors & exec pay.
AI Summary
Lyra Therapeutics, Inc. filed its definitive proxy statement on April 4, 2025, for its annual meeting of stockholders. The filing details information regarding the election of directors, executive compensation, and other corporate governance matters for the fiscal year ending December 31, 2024. The company is seeking stockholder approval for various proposals to be voted on at the upcoming meeting.
Why It Matters
This filing provides crucial information for shareholders to make informed decisions regarding company leadership and strategic direction at the upcoming annual meeting.
Risk Assessment
Risk Level: medium — Proxy statements can reveal changes in leadership, compensation, or strategic direction that may impact stock performance.
Key Numbers
- 2024 — Fiscal Year End (The proxy statement covers matters related to the fiscal year ending December 31, 2024.)
- 20250404 — Filing Date (The definitive proxy statement was filed on this date.)
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Filer of the DEF 14A
- 0001327273 (company) — Central Index Key for Lyra Therapeutics, Inc.
- 20250404 (date) — Filing date of the DEF 14A
- 20250514 (date) — Conformed period of report
- 1231 (date) — Fiscal year end
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide stockholders with information required for the annual meeting, including details on director elections, executive compensation, and other corporate governance matters.
Who is the filer of this document?
The filer is Lyra Therapeutics, Inc., identified by Central Index Key 0001327273.
When was this definitive proxy statement filed?
This definitive proxy statement was filed on April 4, 2025.
What fiscal year does this filing pertain to?
The filing pertains to the fiscal year ending December 31, 2024.
What are some key areas covered in the proxy statement?
Key areas include the election of directors, executive compensation, and other corporate governance proposals.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 4, 2025 regarding Lyra Therapeutics, Inc. (LYRA).